Eltrombopag for management of <font color="red">chronic_2</font> <font color="red">immune_2</font> <font color="red">thrombocytopenia_2</font> ( RAISE ) : a 6-month , randomised , phase 3 study . 
<br>
<br> BACKGROUND Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia . We aimed to compare the response to once daily eltrombopag versus placebo <font color="red">in_1</font> <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">chronic_5</font> <font color="red">immune_5</font> <font color="red">thrombocytopenia_5</font> <font color="red">during_1</font> <font color="red">a_1</font> <font color="red">6-month_1</font> <font color="red">period_1</font> <font color="red">._1</font> 
<br> METHODS <font color="red">We_1</font> <font color="red">undertook_1</font> <font color="red">a_1</font> <font color="red">phase_1</font> <font color="red">3_1</font> <font color="red">,_1</font> <font color="red">double_1</font> <font color="red">-_1</font> <font color="red">blind_1</font> <font color="red">,_1</font> <font color="red">placebo_1</font> <font color="red">-_1</font> <font color="red">controlled_1</font> <font color="red">study_1</font> <font color="red">in_1</font> <font color="red">adults_4</font> <font color="red">with_4</font> <font color="red">previously_4</font> <font color="red">treated_4</font> <font color="red">immune_4</font> <font color="red">thrombocytopenia_4</font> <font color="red">of_4</font> <font color="red">more_4</font> <font color="red">than_4</font> <font color="red">6_4</font> <font color="red">months_4</font> <font color="red">'_4</font> <font color="red">duration_4</font> <font color="red">who_4</font> <font color="red">had_4</font> <font color="red">baseline_4</font> <font color="red">platelet_4</font> <font color="red">counts_4</font> <font color="red">lower_4</font> <font color="red">than_4</font> <font color="red">30,000_4</font> <font color="red">per_4</font> <font color="red">μL._4</font> <font color="red">Patients_2</font> <font color="red">were_2</font> <font color="red">randomly_2</font> <font color="red">allocated_2</font> <font color="red">(_1</font> <font color="red">in_1</font> <font color="red">a_1</font> <font color="red">2:1_1</font> <font color="red">ratio_1</font> <font color="red">)_1</font> <font color="red">treatment_1</font> <font color="red">with_1</font> <font color="red">local_1</font> <font color="red">standard_1</font> <font color="red">of_1</font> <font color="red">care_1</font> <font color="red">plus_1</font> <font color="red">50_1</font> <font color="red">mg_1</font> <font color="red">eltrombopag_1</font> <font color="red">or_1</font> <font color="red">matching_1</font> <font color="red">placebo_1</font> <font color="red">once_1</font> <font color="red">daily_1</font> <font color="red">for_1</font> <font color="red">6_1</font> <font color="red">months_1</font> <font color="red">._1</font> Randomisation was done centrally with a computer - generated randomisation schedule and was <font color="red">stratified_1</font> <font color="red">by_1</font> <font color="red">baseline_1</font> <font color="red">platelet_1</font> <font color="red">count_1</font> <font color="red">(_1</font> <font color="red">≤_1</font> <font color="red">15,000_1</font> <font color="red">per_1</font> <font color="red">μL_1</font> <font color="red">)_1</font> <font color="red">,_1</font> <font color="red">use_1</font> <font color="red">of_1</font> <font color="red">treatment_1</font> <font color="red">for_1</font> <font color="red">immune_1</font> <font color="red">thrombocytopenia_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">splenectomy_1</font> <font color="red">status_1</font> <font color="red">._1</font> <font color="red">Patients_2</font> <font color="red">,_2</font> <font color="red">investigators_2</font> <font color="red">,_2</font> <font color="red">and_2</font> <font color="red">those_2</font> <font color="red">assessing_2</font> <font color="red">data_2</font> <font color="red">were_2</font> <font color="red">masked_2</font> <font color="red">to_2</font> <font color="red">allocation_2</font> <font color="red">._2</font> Dose modifications were made on the basis of platelet response . <font color="red">Patients_1</font> <font color="red">were_1</font> <font color="red">assessed_1</font> <font color="red">for_1</font> <font color="red">response_1</font> <font color="red">to_1</font> <font color="red">treatment_1</font> ( defined as a platelet count of 50,000 - 400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus placebo . Analysis was by intention to treat . This study is registered at ClinicalTrials.gov , number NCT00370331 . 
<br> FINDINGS <font color="red">Between_2</font> <font color="red">Nov_2</font> <font color="red">22_2</font> <font color="red">,_2</font> <font color="red">2006_2</font> <font color="red">,_2</font> <font color="red">and_2</font> <font color="red">July_2</font> <font color="red">31_2</font> <font color="red">,_2</font> <font color="red">2007_2</font> <font color="red">,_2</font> <font color="red">197_5</font> <font color="red">patients_5</font> <font color="red">were_1</font> <font color="red">randomly_1</font> <font color="red">allocated_1</font> <font color="red">to_1</font> <font color="red">treatment_1</font> <font color="red">groups_1</font> and were included in the intention - to - treat analysis ( 135 eltrombopag , 62 placebo ) . <font color="red">106_1</font> <font color="red">(_1</font> <font color="red">79%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">eltrombopag_1</font> <font color="red">group_1</font> <font color="red">responded_1</font> <font color="red">to_1</font> <font color="red">treatment_1</font> <font color="red">at_1</font> <font color="red">least_1</font> <font color="red">once_1</font> <font color="red">during_1</font> <font color="red">the_1</font> <font color="red">study_1</font> <font color="red">,_1</font> <font color="red">compared_1</font> <font color="red">with_1</font> <font color="red">17_1</font> <font color="red">(_1</font> <font color="red">28%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">placebo_1</font> <font color="red">group_1</font> <font color="red">._1</font> <font color="red">The_1</font> <font color="red">odds_1</font> <font color="red">of_1</font> <font color="red">responding_1</font> <font color="red">were_1</font> <font color="red">greater_1</font> <font color="red">in_1</font> <font color="red">patients_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">eltrombopag_1</font> <font color="red">group_1</font> compared with those in the placebo group throughout the 6-month treatment period ( odds ratio 8·2 , 99% CI 3·59 - 18·73 ; p<0·0001 ) . <font color="red">37_1</font> <font color="red">(_1</font> <font color="red">59%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">receiving_1</font> <font color="red">eltrombopag_1</font> <font color="red">reduced_1</font> <font color="red">concomitant_1</font> <font color="red">treatment_1</font> versus ten ( 32% ) patients receiving placebo ( p=0·016 ) . <font color="red">24_1</font> <font color="red">(_1</font> <font color="red">18%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">receiving_1</font> <font color="red">eltrombopag_1</font> <font color="red">needed_1</font> <font color="red">rescue_1</font> <font color="red">treatment_1</font> compared with 25 ( 40% ) patients receiving placebo ( p=0·001 ) . <font color="red">Three_1</font> <font color="red">(_1</font> <font color="red">2%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">receiving_1</font> <font color="red">eltrombopag_1</font> <font color="red">had_1</font> <font color="red">thromboembolic_1</font> <font color="red">events_1</font> compared with none in patients on placebo . Nine ( 7% ) eltrombopag - treated patients and two ( 3% ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4% ) eltrombopag - treated patients ( vs none allocated to placebo ) had increases in total bilirubin . <font color="red">Four_1</font> <font color="red">(_1</font> <font color="red">7%_1</font> <font color="red">)_1</font> <font color="red">patients_1</font> <font color="red">taking_1</font> <font color="red">placebo_1</font> <font color="red">had_1</font> <font color="red">serious_1</font> <font color="red">bleeding_1</font> <font color="red">events_1</font> <font color="red">,_1</font> compared with one ( < 1% ) patient treated with eltrombopag . 
<br> INTERPRETATION Eltrombopag is effective for management of chronic immune thrombocytopenia , and <font color="red">could_1</font> <font color="red">be_1</font> <font color="red">particularly_1</font> <font color="red">beneficial_1</font> <font color="red">for_1</font> <font color="red">patients_3</font> <font color="red">who_2</font> <font color="red">have_2</font> <font color="red">not_2</font> <font color="red">responded_2</font> <font color="red">to_2</font> <font color="red">splenectomy_2</font> <font color="red">or_2</font> <font color="red">previous_2</font> <font color="red">treatment_2</font> <font color="red">._2</font> These benefits should be balanced with the potential risks associated with eltrombopag treatment . 
<br> FUNDING GlaxoSmithKline .